AFT appoints Andrew Lane as independent director

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





28 September 2023
AFT appoints Andrew Lane as independent director
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces the appointment of
Andrew Lane as an independent non-executive director.
The appointment fills the vacancy left by Jon Lamb who retires from the board today
following his 11-year tenure.
Chair David Flacks says: “We are delighted to welcome Andrew to our board. He has
outstanding experience as a senior business executive in international growth markets,
having most recently led Abbott Laboratories Pharmaceutical Division with turnover
growing from NZ$4 Bil to over NZ$9 Bil during his tenure.
“This unique experience is highly relevant to AFT as we grow and consolidate our
position in Australasia and build our presence internationally with our Maxigesic® pain
relief and other medications.”
Andrew says: “I am excited by the opportunity to assist AFT with its growth aspirations
and will be using my accumulated knowledge in finance, sales and marketing within
general, regional and global management for this.”
The board has determined that Andrew Lane is an Independent Director (within the
meaning of the NZX Listing Rules).

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over the counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com.